• 4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections
  • 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest from investigators and patients
  • 4FRONT-2 52-week topline data is expected in H2 2027